Cargando…
Biosimilars: what do patients need to consider?
A view from the EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (SCPARE) on some of the issues that patients might wish to consider about biosimilars in shared decision-making discussions with their rheumatologist. The paper also points to the need for more information on bios...
Autor principal: | Skingle, Diana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623364/ https://www.ncbi.nlm.nih.gov/pubmed/26535149 http://dx.doi.org/10.1136/rmdopen-2015-000141 |
Ejemplares similares
-
Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?
por: Toussirot, Eric, et al.
Publicado: (2017) -
Biosimilar therapeutics—what do we need to consider?
por: Schellekens, Huub
Publicado: (2009) -
Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example
por: Lai, Zhihong, et al.
Publicado: (2016) -
Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis
por: Lindström, Ulf, et al.
Publicado: (2019) -
Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database
por: Stajszczyk, Marcin, et al.
Publicado: (2023)